Harvard Bioscience, Inc.
HBIO Healthcare Medical Instruments & Supplies
Harvard Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $86.6 million, down 8.06% from fiscal 2024. In the quarter to June 2026, revenue grew 11.1%, EPS fell 28.0%, free cash flow fell 123.4% and total debt rose 5.21%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow HBIO
Harvard Bioscience, Inc. (HBIO) EV/Sales
As of 16 October 2026, Harvard Bioscience, Inc. (HBIO) trades at a EV/Sales of 1.1×. Over the past ten years it has ranged from 0.8× (November 2016) to 17.2× (March 2015); the current reading is higher than 30% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.1× | (37.76%) |
| FY2024 | 1.7× | (27.35%) |
| FY2023 | 2.3× | 71.84% |
| FY2022 | 1.4× | (50.50%) |
| FY2021 | 2.7× | 35.80% |
| FY2020 | 2.0× | 45.38% |
| FY2019 | 1.4× | (0.81%) |
| FY2018 | 1.4× | (10.90%) |
| FY2017 | 1.6× | 52.48% |
| FY2016 | 1.0× | (13.18%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.0× | 5.57% |
| Mar 2026 | 1.0× | (5.59%) |
| Dec 2025 | 1.1× | 13.35% |
| Sep 2025 | 0.9× | 1.39% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DXR Daxor Corporation compare | −14.4× |
| MBOT Microbot Medical Inc. compare | −2.9× |
| RVP Retractable Technologies, Inc. compare | −0.6× |
| BNGO Bionano Genomics, Inc. compare | 0.7× |
| POCI Precision Optics Corp. compare | 0.9× |
| HBIO Harvard Bioscience, Inc. | 1.1× |
| NEPH Nephros Inc. compare | 1.7× |
| MLSS Milestone Scientific, Inc. compare | 3.1× |
| ZTEKF Zentek Ltd. compare | 288× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)